Patents by Inventor Nagaraj Gowda

Nagaraj Gowda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS
    Publication number: 20240100024
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 28, 2024
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Nagaraj Gowda
  • PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS
    Publication number: 20230227483
    Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.
    Type: Application
    Filed: July 6, 2022
    Publication date: July 20, 2023
    Inventors: Pravin IYER, Sanjib DAS, Murugan CHINNAPATTU, Sachin CHAUDHARI, Jagmohan SAINI, Sravan MANDADI, Nagaraj GOWDA, Dnyaneshwar DAHALE, Sandip PATIL, Nanasaheb KADLAG, Chandrasekhar MISRA, Priyanka PANGARE
  • DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS
    Publication number: 20230062570
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: October 7, 2022
    Publication date: March 2, 2023
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty S. Naremaddepalli, Nagaraj Gowda
  • INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS
    Publication number: 20230009626
    Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.
    Type: Application
    Filed: October 7, 2019
    Publication date: January 12, 2023
    Inventors: Sachin Sundarlal CHAUDHARI, Laxmikant Atmaram GHARAT, Pravin IYER, Sachin Vasantrao DHONE, Bharat Gangadhar ADIK, Prashant Dilip WADEKAR, Nagaraj GOWDA, Malini BAJPAI
  • Dual inhibitors of TIM-3 and PD-1 pathways
    Patent number: 11497734
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 15, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty S. Naremaddepalli, Nagaraj Gowda
  • DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS
    Publication number: 20200368210
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: October 31, 2018
    Publication date: November 26, 2020
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Sethy S. Naremaddepalli, Nagaraj Gowda